Best Prescription Weight Loss Pills: Qsymia UK

Qsymia, a combination of phentermine and topiramate approved in the US, is not licensed in the UK and cannot be routinely prescribed here. For patients seeking the best prescription weight loss pills, the UK offers several MHRA-authorised options, including orlistat, semaglutide (Wegovy), tirzepatide (Mounjaro), and orforglipron (Foundayo). This article explains why Qsymia is unavailable in the UK, how licensed alternatives work, what side effects to expect, and how to access treatment through the NHS or a regulated private provider.

Is Qsymia available on prescription in the UK?

Qsymia is not licensed by the MHRA and cannot be routinely prescribed in the UK; purchasing it from unverified online sources carries serious safety risks.

Qsymia holds no marketing authorisation from the MHRA and is not licensed for use in Great Britain or Northern Ireland.^[1] Qsymia is a combination product containing phentermine and topiramate that is approved by the US Food and Drug Administration (FDA) for weight management, but it has never received a European or UK licence.^[2] Because it is an unlicensed medicine in the UK, no registered UK prescriber can routinely prescribe it through a standard clinical pathway, and it cannot be dispensed by a GPhC-registered pharmacy as a routine prescription item. In exceptional circumstances, unlicensed medicines may be supplied on a named-patient basis under strict regulatory conditions, but this route cannot be promoted and is not a standard or accessible pathway for weight management.

Searching online for Qsymia as a UK weight loss option can lead patients towards unregulated websites that may supply counterfeit or substandard medicines. The MHRA strongly advises against purchasing prescription-only medicines from unverified online sources, as there is no guarantee of safety, quality or authenticity. Patients who have seen Qsymia referenced in US-based media or research should be aware that US prescribing rules and approved medicines do not automatically apply in the UK.

The UK does have a range of MHRA-authorised prescription medicines for weight management, and NICE has issued guidance on their use within the NHS. These licensed options have been evaluated for safety and efficacy within the UK regulatory framework and are the appropriate starting point for anyone seeking medical support with weight loss. The sections below explain how these medicines work and how to access them.

How do prescription weight loss medicines work in the body?

Licensed UK weight loss medicines work by suppressing appetite via GLP-1 or dual GLP-1/GIP receptor pathways, or by blocking dietary fat absorption in the gut, as with orlistat.

Licensed prescription weight loss medicines work through several distinct mechanisms, broadly targeting appetite regulation, energy intake, or nutrient absorption. Understanding these mechanisms helps patients and clinicians choose the most appropriate option based on individual health needs and medical history.

GLP-1 receptor agonists, such as semaglutide (Wegovy) and liraglutide (Saxenda), mimic the action of the naturally occurring hormone glucagon-like peptide-1. This hormone is released after eating and acts on receptors in the brain, particularly in the hypothalamus, to reduce appetite and increase feelings of fullness.^[24][23] GLP-1 receptor agonists also slow gastric emptying, meaning food moves more slowly through the stomach, which prolongs satiety. Tirzepatide (Mounjaro) acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, a dual mechanism that has been shown in clinical trials to produce substantial reductions in body weight, as reflected in NICE technology appraisals for these medicines.

Orlistat, available both on prescription and over the counter at lower doses, works differently. It inhibits pancreatic and gastric lipases, the enzymes responsible for breaking down dietary fat in the gut. According to the Xenical (orlistat) SmPC, approximately one third of ingested fat passes through the digestive system unabsorbed at the prescribed dose, reducing overall calorie intake.^[4][3] This mechanism is entirely peripheral and does not affect the brain or appetite centres directly.

Orforglipron (Foundayo) is a newer oral GLP-1 receptor agonist that has received a UK marketing authorisation for chronic weight management.^[8][9] It works through a similar appetite-regulating mechanism to injectable GLP-1 receptor agonists but is taken as a tablet rather than an injection.

All of these medicines are intended to be used alongside a reduced-calorie diet and increased physical activity. They are not standalone solutions and are most effective when combined with structured lifestyle support. The degree of weight loss achieved varies between individuals and between medicines, and a prescriber will consider a patient's full medical history before recommending any specific treatment.

What weight loss pills can UK doctors actually prescribe?

UK doctors can prescribe orlistat, liraglutide, semaglutide, tirzepatide, oral semaglutide (Wegovy tablets), and orforglipron, each with specific BMI and clinical eligibility criteria.

UK doctors can prescribe several MHRA-authorised medicines for chronic weight management, each with specific eligibility criteria and licensed indications. The main options currently available are orlistat (Xenical), liraglutide (Saxenda), semaglutide (Wegovy), tirzepatide (Mounjaro), oral semaglutide (Wegovy 25 mg tablets), and orforglipron (Foundayo).

Orlistat (Xenical) is the longest-established prescription option and is also available over the counter as Alli at a lower dose. It is licensed for adults with a BMI of 30 kg/m² or above, or 28 kg/m² or above in the presence of weight-related risk factors such as type 2 diabetes or hypertension.^[11][4] Liraglutide (Saxenda) is a once-daily injectable GLP-1 receptor agonist licensed for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity.^[12][13]

Semaglutide (Wegovy) is a once-weekly injectable GLP-1 receptor agonist available in doses up to 2.4 mg, with a higher-dose 7.2 mg strength also authorised by the MHRA. Tirzepatide (Mounjaro) is authorised in the UK both for type 2 diabetes and for chronic weight management, making it one of the most recently licensed options with a dual GLP-1 and GIP mechanism. An oral formulation of semaglutide for weight management, Wegovy 25 mg tablets, received MHRA authorisation in June 2026 and represents a newer option for patients who prefer not to inject.^[16] Orforglipron (Foundayo) is an oral GLP-1 receptor agonist that has also received a UK marketing authorisation for chronic weight management, providing a further non-injectable choice.^[8][9]

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered. Eligibility for any of these medicines depends on individual clinical assessment, and a prescriber will weigh benefits against risks for each patient.

What are the side effects and safety risks to know about?

GLP-1 medicines commonly cause nausea and gastrointestinal upset, with rarer risks including acute pancreatitis; orlistat causes oily stools and reduces fat-soluble vitamin absorption.

Prescription weight loss medicines carry a range of side effects and safety considerations that patients should discuss with their prescriber or pharmacist before starting treatment. The profile of adverse effects differs between medicine classes.

For GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, liraglutide, tirzepatide, orforglipron), the most commonly reported side effects are gastrointestinal, including nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These effects are typically most pronounced during dose escalation and tend to improve over time. Acute pancreatitis has been reported in association with this medicine class, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome; patients should seek prompt medical attention if they develop severe and persistent abdominal pain. Gallbladder-related conditions, including gallstones, have also been reported.

For orlistat, side effects are primarily gastrointestinal and relate directly to its mechanism: oily or fatty stools, faecal urgency, and increased frequency of bowel movements are common, particularly if dietary fat intake remains high. Orlistat can also reduce the absorption of fat-soluble vitamins (A, D, E and K), so a multivitamin supplement taken at a different time of day is often recommended. Orlistat may also affect the absorption of some other medicines, including warfarin and ciclosporin, so patients taking these should inform their prescriber or pharmacist.

Patients taking GLP-1 receptor agonists who have pre-existing diabetic eye disease, particularly pre-proliferative or proliferative retinopathy, should be aware that rapid improvements in blood glucose control may be associated with transient worsening of their condition, and regular ophthalmology review is important. Women of childbearing potential should note that tirzepatide and semaglutide are not recommended during pregnancy or breastfeeding. The UK SmPC for tirzepatide advises using an additional non-oral contraceptive method for four weeks after starting and four weeks after each dose increase, as oral contraceptive absorption may be affected.^[19][20]

Suspected side effects from any licensed medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you experience a severe allergic reaction, call 999 immediately. For urgent but non-emergency concerns, contact NHS 111 or speak to your GP.

How do I get a prescription for weight loss medicine through the NHS?

NHS access starts with a GP assessment against NICE criteria, though availability varies by nation and local commissioning; regulated private providers are an alternative if NHS access is limited.

NHS access to prescription weight loss medicines begins with a conversation with your GP, who can assess your eligibility based on your BMI, medical history and any weight-related health conditions. NICE has published technology appraisals on the use of medicines such as orlistat, semaglutide (Wegovy) and tirzepatide (Mounjaro) within the NHS in England. However, access and commissioning arrangements differ across the four nations. In England, local Integrated Care Boards (ICBs) make commissioning decisions about which treatments are funded in their area.^[23] In Scotland, the Scottish Medicines Consortium (SMC) advises on NHS Scotland use. In Wales, the All Wales Medicines Strategy Group (AWMSG) and its advisory body provide equivalent guidance. In Northern Ireland, the Health and Social Care Board and the Department of Health advise on medicines access. This means availability can vary considerably depending on where you live.

For NHS prescribing, NICE guidance generally requires that weight management medicines are used as part of a comprehensive programme that includes dietary advice, physical activity support and behavioural change.^[21][22] Medicines are typically continued only if a patient achieves a clinically meaningful reduction in weight within a defined period, as specified in the relevant NICE technology appraisal for each medicine. Your GP or a specialist weight management service can advise on local pathways and waiting times.

If NHS access is limited in your area or waiting times are lengthy, some patients choose to seek a private prescription through a regulated online or in-person service. When considering any private provider, check that the pharmacy is registered with the GPhC (for pharmacies in Great Britain) or the PSNI (for pharmacies in Northern Ireland), and that any prescriber is registered with the GMC (gmc-uk.org) or the relevant professional body. Avoid any website that offers prescription medicines without a clinical consultation, as this is both unsafe and unlawful.

Regardless of the route taken, weight loss medicines work best when supported by sustainable lifestyle changes. Regular follow-up with a healthcare professional helps to monitor progress, manage side effects and adjust treatment as needed.

Scientific References

1. Qsiva (phentermine/topiramate) EPAR – CHMP refusal of marketing authorisation.
2. The FDA's Assessment of Two Drugs for Chronic Weight Management.
3. Orlistat: a medicine to treat obesity.
4. Xenical 120 mg hard capsules – Summary of Product Characteristics.
5. Xenical (orlistat) EPAR – Scientific Discussion.
6. Xenical (orlistat) EPAR – Product Information.
7. UK first in Europe to authorise orforglipron (Foundayo) for weight management and type 2 diabetes.
8. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
9. Mounjaro (tirzepatide) EPAR.
10. Tirzepatide – BNF Drug Monograph.
11. Orlistat – BNF Drug Monograph.
12. Liraglutide – BNF Drug Monograph.
13. Saxenda (liraglutide) EPAR.
14. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
15. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
16. First GLP-1 tablet for weight loss approved in the UK (Wegovy 25 mg tablets; authorisation granted 11 June 2026).
17. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
18. Orlistat-associated adverse effects and drug interactions. Filippatos TD et al. Int J Clin Pract. 2008..
19. Mounjaro KwikPen 10 mg solution for injection in pre-filled pen – Summary of Product Characteristics.
20. Women on 'skinny jabs' must use effective contraception – MHRA guidance.
21. A guide for prescribing medicines to manage overweight and obesity.
22. NICE recommended weight-loss drug (semaglutide/Wegovy) to be made available in specialist NHS services.
23. Overweight and obesity in adults.
24. Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety. Nature Metabolism. 2024..

Frequently Asked Questions